In February 2025, Gan & Lee Pharmaceuticals (hereafter referred to as "Gan & Lee," stock code: 603087.SH) unveiled that the first participant was successfully dosed in a large-scale Phase 3 clinical trial (OPTIMUM-2) of Bofanglutide, a bi-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA) independently, in Chinese participant with type 2 diabetes mellitus (T2DM)
It must be adapted based on medical history, response to treatment, and overall health
Over time, patterns emerge that help distinguish drug effects from disease activity
Those with lupus should avoid exercising during peak sun exposure and should monitor for exercise-induced flares
How deep is Mounjaro injected
And if youd like a broader view of whats available, our Facebook page is a great place to stay connected and ask questions